
Ugur Sahin
Fortuna: 3 729 M $ al 30/06/2026

Fortuna: 3 729 M $ al 30/06/2026
Fundador de BioNTech SE, Ganymed Pharmaceuticals AG, Ci3 Management UG y TRON - Translationale Onkologie an der Universittsmedizin der, Ugur Sahin es actualmente Consejero Delegado de BioNTech SE y Director General de reBOOST Management GmbH (filial de BioNTech SE) y Director General de Medine GmbH. El Dr. Sahin es también profesor en la Universittsmedizin der Johannes Gutenberg-Universitt Mainz. Anteriormente ocupó el cargo de director médico de Ganymed Pharmaceuticals AG y codirector general de TRON - Translationale Onkologie an der Universittsmedizin der. El Dr. Sahin se doctoró en la Universitt zu Kln.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
BIONTECH SE 16,59 % | 31/03/2026 | 40.076.320 ( 16,59 % ) | 3 729 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| BIONTECH SE | Director Ejecutivo | 02/06/2008 |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Director Ejecutivo | 23/10/2018 |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Director Ejecutivo | 14/03/2011 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Corporate Officer/Principal | 01/01/2014 |
Helmholtz Institute For Translational Oncology | Corporate Officer/Principal | - |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Director Ejecutivo | - |
| Empresas | Cargo | Fin |
|---|---|---|
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Director Ejecutivo | 01/01/2019 |
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Fundador | 30/07/2010 |
Ci3 Management UG | Fundador | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Health Technology |
Universität zu Köln
Universität zu Köln Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Health Services |
Ci3 Management UG | |
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Commercial Services |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Commercial Services |
Helmholtz Institute For Translational Oncology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.